- Home
- ANL vs INMB Comparison
ANL vs INMB Comparison
Compare ANL & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | INMB |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 49.2M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANL | INMB |
|---|---|---|
| Price | $1.42 | $1.84 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $4.30 |
| AVG Volume (30 Days) | 31.4K | ★ 494.4K |
| Earning Date | 04-20-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | $173.21 |
| Revenue Next Year | N/A | $12,733.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.05 |
| 52 Week Low | $0.88 | $1.38 |
| 52 Week High | $2.99 | $11.64 |
Technical Indicators
Market Signals| Indicator | ANL | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 50.49 |
| Support Level | $1.42 | $1.75 |
| Resistance Level | $1.70 | $2.30 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 65.39 | 38.82 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.